Additional analysis demonstrates an important pre-specified secondary clinical outcome endpoint, major adverse cardiac events (MACE), achieved statistical significance with 8 events in the standard of ...

Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic ...

A new preprint links the company’s cell therapy to less brain inflammation in Alzheimer’s, just as it heads out on an ...

Longeveron Inc. a annoncé que, le 7 octobre 2026, la Dre Nataliya Agafonova a informé la direction de Longeveron Inc. de sa décision de quitter ses fonctions de directrice médicale, avec effet ...

Longeveron Inc. gab bekannt, dass Dr. Nataliya Agafonova das Management von Longeveron Inc. am 7. Oktober 2026 über ihre ...

Il 7 ottobre 2026, la dottoressa Nataliya Agafonova ha informato il management di Longeveron Inc. della decisione di lasciare l'incarico di direttrice medica, con effetto dal 14 ottobre ...

New Data Analysis from Phase 2a Clinical Trial in Alzheimer’s Disease (AD) Indicating That Laromestrocel Treatment May Reduce Neuroinflammation in the Brain, A Core Driver of AD Pathogenesis, Publishe ...

An update from Longeveron ( ) is now available. On September 16, 2026, Longeveron reported topline results from its ELPIS II Phase 2b trial of laromestrocel in 40 infants with hyp ...

Washburn stated, "We currently anticipate our current existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditures into the fourth quarter of 26," ...

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities ...

MIAMI, April 22, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic ...